Delcath Systems, Inc.

Website Links

Description

Expanded Access Program: For patients who cannot participate in a clinical trial of an investigational drug, but have a serious disease or condition that may benefit from treatment with the drug, FDA regulations enable manufacturers of such drugs to provide those patients access to the drug under certain situations, known as “expanded access.” The intent of expanded access is to provide treatment for a patient’s disease or condition, rather than to collect data about the study drug.

Delcath will not sell or rent personally identifiable information to third parties. However, sometimes selected third parties are used to provide us with support services in connection with the Site and such parties may, from time to time, have access to your information to enable them to provide those services to Delcath. Please rest assured that all companies providing such support services are required by us to meet the same standards of data protection as Delcath and are prohibited from using the information for their own purposes.

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan HDS)-is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company's principal focus is on the treatment of primary and metastatic liver cancers.

Products & services

Similar companies nearby